Explore

Oncolytic Virotherapy Summit

Oncolytic Virotherapy Summit 2019

The Westin Boston Waterfront, 425 Summer Street, Boston, Massachusetts, 02210, United States
03 December 2019
The conference ended on 03 December 2019

Important Dates

Abstract Submission Deadline
2nd December 2019

About Oncolytic Virotherapy Summit

Optimize the Immune Response to Cancer with Viral Vehicles. The roadmap to oncolytic virotherapy success

Topics

Conferences, Pharmaceuticals

Call for Papers

The Oncolytic Virotherapy Summit is back for its fifth year as the only conference to bring together industry leaders, clinicians and academic experts focused on finding an effective immuno-oncology.

Over 3 days packed with compelling case studies, diverse panels and varied networking opportunities, you'll glean insights from industry and academic leaders. The 2019 agenda will reflect the strides taken by the community over the past year as well as forming the future of oncolytic virus development.

Time: 08:00 to 16:00

Speakers: Lance Weed, Vice President Operations, uniQure, Anton Xavier, Founder, K9 Biotech, Michael Wood MBA, Founder and Chief Operating Officer, OncoMyx, Robert Coffin, CEO, Replimmune, Daniel Katzman, CEO, Unleash Immuno Oncolytics, Dr Erik Digman Wiklund, Chief Business Officer, Targovax ASA, Michael Moore, Vice President Investor Relations and Corporate Communications, Oncolytics Biotech, David Sherris, President and Chief Executive Officer, GenAdam Therapeutics Inc., Louis Cantolupo, Chief Operating Officer, Unleash Immuno Oncolytics, Christophe Quéva, Chief Scientific Officer, Oncorus, Sridhar Pennathur, Senior Director and Fellow Biopharmaceutical Development, AstraZeneca, Dr John Goldberg, Senior Vice President Clinical Development and Practicing Paediatric Oncologist, Oncorus, Brian Haines PhD, Senior Director Pharmacology and Toxicology, Oncorus, Lorena Lerner, Vice President Molecular Biology and Virology, Oncorus, Beatriz Mesa, Senior Director Oncolytic Virus Manufacturing, Sorrento Therapeutics, Steve Thorne, Chief Scientific Officer, Western Oncolytics, Shara Dellatore, Principal Scientist and Group Leader, Merck, Angelica Loskog, CEO, Lokon Pharma, Maritza McIntyre, Former Chief Gene Therapy Branch, FDA

Prices: Conference Only : USD 2399.0, Conference + 1 Workshop: USD 2999.0, Conference + 2 Workshops: USD 3399.0

Keep Up to Date with PaperCrowd

Sign up and follow your favorite conferences.

We are no longer accepting conference submissions on PaperCrowd. We apologise for any inconvenience.